Recent PhD graduate Tatiana Blanchard shares her story as a scientist, talks about what it has been like doing research on Ewing sarcoma,...

Dave Hallett gives an overview of Exscientia and describes how important testing compounds in the company's labs has been to its...

Lian Ni Lee and Susannah de Jager discuss how quickly Infinitopes has been able to get ready for the clinic.

He will be presenting final data from a 21 patient NHL cohort at the 2024 ASCO Annual Meeting in June.

Professor Matthew Wood explains the idea behind this biotech startup incubator and also shares his expertise on the latest in neuroscience.

She describes OMass' platform and rare disease focus.

OSE Partner Claire Brown describes the important role that OSE plays in the helping to turn ideas into companies at Oxford.

Alek Safarian shares his opinions on the current funding environment for biotech, and introduces us to his firm and its investment...

LabGenius is combining in silico design and automation to optimize antibody design, oftentimes with a non-obvious result.

In a wide ranging interview, Emma Walmsley discusses GSK's R&D activities in its four main areas of focus.

Kristen Albright describes Prokarium's bladder cancer program, which went into the clinic earlier this year, and a platform (including a...

Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.

He explains the decision to withdraw e-therapeutics from London AIM and describes the HepNet and GalOmic platforms that have produced the...

He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over...

He describes the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise.

He describes how Cloverleaf believes it is different from other tRNA companies and how it has already at the earliest stages benefitted...

CEO Murat Cirit describes how the liver tissue chip and accompanying software is meant to improve the quality of preclinical research.

Jing Wang explains how her company is focused on restoring CNS conditions such as MS and ALS, and talks targets.

McKinsey Boston life science specialists give their take on the goals of the summit and the current state of the sector.

Chris Bahl walks through the attributes of miniproteins.